Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects

Peter T. TheunissenCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; ;Medicines Evaluation Board, Utrecht, The Netherlands; ;Innovative Testing in Life Sciences and Chemistry, University of Applied Sciences Utrecht (HU), Utrecht, The Netherlands; Correspondence[email protected]

Sonia BekenFederal Agency for Medicines and Health Products, Brussels, Belgium;

Bruce BeyerSanofi U.S. Inc, Bridgewater, NJ, USA;

William J. BreslinLilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA;

Gregg D. CapponPfizer Worldwide Research & Development, Groton, CT, USA;

Connie L. ChenILSI-Health and Environmental Sciences Institute, Washington, DC, USA;

Gary ChmielewskiCovance Laboratories Inc, Greenfield, IN, USA;

Luc de SchaepdrijverPreclinical Development & Safety, Beerse, Belgium;

Brian EnrightAbbVie Inc, North Chicago, IL, USA;

Jennifer E. ForemanExxonMobil Biomedical Sciences, Inc, Annandale, NJ, USA;

Wafa HarroukUS Food & Drug Administration, Silver Spring, MD, USA;

Kok-Wah HewTakeda Pharmaceutical Company, Deerfield, IL, USA;

Alan M. HobermanPreclinical Services, Charles-River Laboratories, Horsham, PA, USA;

Julia Y. HuiCelgene Corporation, Summit, NJ, USA;

Thomas B. KnudsenUS Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park, NC, USA;

Susan B. LaffanSafety Assessment, GlaxoSmithKline, King of Prussia, PA, USA;

Susan L. MakrisNational Center for Environmental Assessment, US Environmental Protection Agency, Washington, DC, USA;

Matthew MartinUS Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park, NC, USA;

Mary Ellen McNerneyDrug Safety Evaluation, Bristol-Myers Squibb, New Brunswick, NJ, USA;

Christine L. SiezenMedicines Evaluation Board, Utrecht, The Netherlands;

Dinesh J. StanislausSafety Assessment, GlaxoSmithKline, King of Prussia, PA, USA;

Jane StewartDrug Safety & Metabolism, AstraZeneca, Macclesfield, UK;

Kary E. ThompsonDrug Safety Evaluation, Bristol-Myers Squibb, New Brunswick, NJ, USA;

Belen TornesiAbbVie Inc, North Chicago, IL, USA;

Jan Willem Van der LaanCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; ;Medicines Evaluation Board, Utrecht, The Netherlands;

Gerhard F. WeinbauerCovance Preclinical Services GmbH, Muenster, Germany;

Sandra WoodMerck Research Laboratories, Upper Gwynedd, PA, USA;

Aldert H. PiersmaCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; ;Faculty of Veterinary Sciences, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands

show all

Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date